UK markets closed
  • NIKKEI 225

    28,930.11
    -628.99 (-2.13%)
     
  • HANG SENG

    29,236.79
    -643.63 (-2.15%)
     
  • CRUDE OIL

    63.95
    +2.67 (+4.36%)
     
  • GOLD FUTURES

    1,694.30
    -21.50 (-1.25%)
     
  • DOW

    30,958.52
    -311.57 (-1.00%)
     
  • BTC-GBP

    34,781.68
    -2,246.45 (-6.07%)
     
  • CMC Crypto 200

    969.05
    -18.16 (-1.84%)
     
  • ^IXIC

    12,768.31
    -229.44 (-1.77%)
     
  • ^FTAS

    3,792.09
    -16.15 (-0.42%)
     

At kr87.50, Is Medicover AB (publ) (STO:MCOV B) Worth Looking At Closely?

Simply Wall St
·4-min read

Medicover AB (publ) (STO:MCOV B), which is in the healthcare business, and is based in Sweden, saw a double-digit share price rise of over 10% in the past couple of months on the OM. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Let’s take a look at Medicover’s outlook and value based on the most recent financial data to see if the opportunity still exists.

Check out our latest analysis for Medicover

Is Medicover still cheap?

Medicover is currently expensive based on my price multiple model, where I look at the company's price-to-earnings ratio in comparison to the industry average. In this instance, I’ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock’s cash flows. I find that Medicover’s ratio of 47.4x is above its peer average of 18.64x, which suggests the stock is trading at a higher price compared to the Healthcare industry. Another thing to keep in mind is that Medicover’s share price is quite stable relative to the rest of the market, as indicated by its low beta. This means that if you believe the current share price should move towards the levels of its industry peers over time, a low beta could suggest it is not likely to reach that level anytime soon, and once it’s there, it may be hard for it to fall back down into an attractive buying range again.

What does the future of Medicover look like?

OM:MCOV B Past and Future Earnings April 23rd 2020
OM:MCOV B Past and Future Earnings April 23rd 2020

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for Medicover. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What this means for you:

Are you a shareholder? MCOV B’s optimistic future growth appears to have been factored into the current share price, with shares trading above industry price multiples. However, this brings up another question – is now the right time to sell? If you believe MCOV B should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on MCOV B for some time, now may not be the best time to enter into the stock. The price has surpassed its industry peers, which means it is likely that there is no more upside from mispricing. However, the optimistic prospect is encouraging for MCOV B, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Medicover. You can find everything you need to know about Medicover in the latest infographic research report. If you are no longer interested in Medicover, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.